Table 3 Univariate and multivariate analyses for demographic, clinical and genetic data with overall survival for colorectal cancer patients treated with FOLFIRI® and bevacizumab (n = 45)

Sex: Male

16 (35.6)

ref.

ref.

ref.

Female

29 (64.4)

0.43 [0.20; 0.90]

0.02

0.38 [0.18; 0.82]

0.01

Age, y: <=65

20 (44.4)

ref.

> 65

25 (55.6)

1.09 [0.52; 2.28]

0.81

-

-

ECOG/PS: 0

16 (35.6)

ref.

1-2

29 (64.4)

1.26 [0.60; 2.70]

0.55

-

-

Primary tumor: Colon

28 (62.2)

ref.

Rectum

17 (37.8)

1.16 [0.56; 2.40]

0.69

-

-

Non-mucinous: No

5 (11.1)

ref.

Yes

40 (88.9)

0.45 [0.15; 1.36]

0.15

-

-

Metastatic sites: 1

13 (28.9)

ref.

>1

32 (71.1)

0.77 [0.36; 1.65]

0.50

-

-

Liver-only metas.: No

33 (73.3)

ref.

Yes

12 (26.7)

1.14 [0.52; 2.52]

0.74

-

-

Resected primary tumor: No

10 (22.2)

ref.

Yes

35 (77.8)

0.67 [0.29; 1.51]

0.33

-

-

Previous adjuvant CT*: No

34 (75.6)

ref.

Yes

11 (24.4)

0.85 [0.36; 1.98]

0.70

-

-

High ALP^†: No

23 (51.1)

ref.

ref.

ref.

Yes

19 (42.2)

2.80 [1.25; 6.26]

<0.009

4.21 [1.44; 12.31]

0.008

High LDH^§: No

16 (35.6)

ref.

Yes

13 (28.9)

4.73 [1.42; 15.81]

<0.006

1.46 [0.62; 3.43]

0.39

High ACE^††: No

17 (37.8)

ref.

Yes

22 (48.9)

2.07 [0.91; 4.72]

0.08

-

-

rs25648: C

34 (75.6)

ref.

ref.

ref.

H/V

11 (24.4)

3.605 [1.57;8.30]

0.01**

3.58 [1.50; 8.57]

0.004

rs2010963: C

17 (37.8)

ref.

H/V

28 (62.2)

1.228 [0.59;2.56]

0.58

-

-

rs699947: C

34 (75.6)

ref.

H/V

11 (24.4)

1.324 [0.59;2.99]

0.50

-

-

rs8175347: C

15 (33.3)

ref.

H/V

30 (66.7)

0.632 [0.30;1.35]

0.23

-

-

3′UTR: C

23 (51.1)

ref.

H/V

22 (48.9)

1.298 [0.64;2.63]

0.47

-

-

5′UTR: V

11 (24.4)

ref.

C/H

33 (73.3)

0.972 [0.44;2.13]

0.94

-

-

5′UTR: C

13 (28.9)

ref.

H/V

31 (68.9)

0.886 [0.41;1.91]

0.76

-

-